

Nicola J Curtin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7836235/publications.pdf>

Version: 2024-02-01

157
papers

17,618
citations

22153
59
h-index

13771
129
g-index

162
all docs

162
docs citations

162
times ranked

19801
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in Durability of PARP Inhibition by PARP Inhibitors in Ovarian Cancer Cells. Medical Sciences Forum, 2021, 3, .	0.5	0
2	Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers, 2021, 13, 1420.	3.7	7
3	Increased Replication Stress Sensitises High Risk Neuroblastoma Cells to ATR and PARP Inhibition. Medical Sciences Forum, 2021, 3, .	0.5	0
4	Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations. Journal of Pathology: Clinical Research, 2021, , .	3.0	3
5	Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells. Cancers, 2021, 13, 6215.	3.7	8
6	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. , 2020, 207, 107450.		101
7	PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer. Cancers, 2020, 12, 3494.	3.7	2
8	Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers, 2020, 12, 1939.	3.7	18
9	Poly(ADP-ribose) polymerase inhibition: past, present and future. Nature Reviews Drug Discovery, 2020, 19, 711-736.	46.4	275
10	DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine, 2020, 22, e2.	3.9	150
11	The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity. Cancers, 2020, 12, 564.	3.7	12
12	ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers, 2020, 12, 1095.	3.7	24
13	Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Frontiers in Oncology, 2020, 10, 371.	2.8	22
14	Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells. Cancers, 2020, 12, 878.	3.7	18
15	Repositioning PARP inhibitors for SARSâ€CoVâ€2 infection(COVIDâ€19); a new multiâ€pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology, 2020, 177, 3635-3645.	5.4	52
16	Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nature Reviews Clinical Oncology, 2019, 16, 725-726.	27.6	19
17	Warburg and Krebs and related effects in cancer. Expert Reviews in Molecular Medicine, 2019, 21, e4.	3.9	22
18	Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers, 2019, 11, 354.	3.7	12

#	ARTICLE	IF	CITATIONS
19	Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. <i>Biochemical Pharmacology</i> , 2019, 167, 125-132.	4.4	9
20	Opportunities for the repurposing of PARP inhibitors for the therapy of non-€oncological diseases. <i>British Journal of Pharmacology</i> , 2018, 175, 192-222.	5.4	160
21	The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation. <i>Cancers</i> , 2018, 10, 275.	3.7	28
22	Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. <i>Blood Advances</i> , 2018, 2, 1157-1169.	5.2	28
23	Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors. <i>Cancer Drug Discovery and Development</i> , 2018, , 63-97.	0.4	0
24	Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. <i>Cancer Medicine</i> , 2018, 7, 4744-4754.	2.8	9
25	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. <i>Oncotarget</i> , 2018, 9, 13139-13153.	1.8	25
26	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017, 7, 620-629.	9.4	321
27	PARP. , 2017, , 913-934.		0
28	PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. <i>NMR in Biomedicine</i> , 2017, 30, e3736.	2.8	14
29	Strategies Employed for the Development of PARP Inhibitors. <i>Methods in Molecular Biology</i> , 2017, 1608, 271-297.	0.9	3
30	Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. <i>Clinical Cancer Research</i> , 2017, 23, 2050-2060.	7.0	60
31	Targeting the ATR-CHK1 Axis in Cancer Therapy. <i>Cancers</i> , 2017, 9, 41.	3.7	156
32	The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients. <i>Methods in Molecular Biology</i> , 2017, 1608, 343-370.	0.9	7
33	Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. <i>Oncotarget</i> , 2017, 8, 69779-69796.	1.8	27
34	Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. <i>Oncotarget</i> , 2017, 8, 113418-113430.	1.8	20
35	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). <i>Oncotarget</i> , 2017, 8, 104478-104491.	1.8	27
36	Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1004-1011.	2.5	9

#	ARTICLE	IF	CITATIONS
37	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. <i>International Journal of Cancer</i> , 2016, 138, 206-216.	5.1	45
38	Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016, 65, 305-313.	3.7	98
39	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 213-223.	4.6	33
40	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 723-730.	6.4	132
41	Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 763-769.	2.5	11
42	mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. <i>Molecular Oncology</i> , 2016, 10, 101-112.	4.6	17
43	Clinico-pathological correlation of homologous recombination status in epithelial ovarian cancer: Surgeon's perspective. , 2016, 02, .		0
44	PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues – A population pharmacokinetic/pharmacodynamic analysis of rucaparib. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 89-98.	1.6	4
45	PARP1 expression, activity and <i>ex vivo</i> sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. <i>Oncotarget</i> , 2015, 6, 43978-43991.	1.8	31
46	Development of pharmacodynamic biomarkers for ATR inhibitors. <i>Molecular Oncology</i> , 2015, 9, 463-472.	4.6	22
47	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 569-585.	4.6	75
48	DNA-PK – A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. <i>Clinical Cancer Research</i> , 2015, 21, 925-933.	7.0	74
49	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2735-2743.	4.1	75
50	Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. <i>PLoS ONE</i> , 2015, 10, e0118187.	2.5	17
51	Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. <i>Oncotarget</i> , 2015, 6, 32396-32409.	1.8	59
52	Biomarkers for PARP Inhibitors. <i>Cancer Drug Discovery and Development</i> , 2015, , 553-579.	0.4	0
53	The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis. <i>PLoS ONE</i> , 2014, 9, e90604.	2.5	42
54	PARP inhibitors target ATM+p53-defective gastric cancer. <i>Cell Cycle</i> , 2014, 13, 3161-3162.	2.6	2

#	ARTICLE	IF	CITATIONS
55	Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. <i>Current Opinion in Oncology</i> , 2014, 26, 428-433.	2.4	36
56	DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 47-55.	2.5	116
57	Inhibition of DNA Repair as a Therapeutic Target. , 2014, , 193-237.		0
58	Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. <i>British Journal of Cancer</i> , 2014, 111, 94-100.	6.4	23
59	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. <i>British Journal of Cancer</i> , 2014, 110, 1977-1984.	6.4	42
60	Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. <i>British Journal of Cancer</i> , 2014, 111, 1319-1326.	6.4	36
61	PARP inhibitors for anticancer therapy. <i>Biochemical Society Transactions</i> , 2014, 42, 82-88.	3.4	78
62	PARP. , 2014, , 1-22.		0
63	1-Substituted (Dibenzo[<i>b,d</i>]thiophen-4-yl)-2-morpholino-4 <i>H</i> -chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6386-6401.	6.4	45
64	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentialiation. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1191-1199.	2.3	164
65	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
66	Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. <i>Molecular Aspects of Medicine</i> , 2013, 34, 1217-1256.	6.4	312
67	Inhibiting the <sc>DNA</sc> damage response as a therapeutic manoeuvre in cancer. <i>British Journal of Pharmacology</i> , 2013, 169, 1745-1765.	5.4	64
68	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, <i>In Vitro</i> and <i>In Vivo</i> in p53 Functional and Dysfunctional Models of Human Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 959-967.	4.1	142
69	Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. <i>Haematologica</i> , 2013, 98, 1397-1406.	3.5	58
70	ATR as a Therapeutic Target. , 2013, , 211-228.		0
71	Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1789-1798.	4.1	112
72	The Role of PARP in DNA Repair and its Therapeutic Exploitation. , 2012, , 55-73.		2

#	ARTICLE	IF	CITATIONS
73	Visualization of a DNA-PK/PARP1 complex. <i>Nucleic Acids Research</i> , 2012, 40, 4168-4177.	14.5	89
74	DNA repair dysregulation from cancer driver to therapeutic target. <i>Nature Reviews Cancer</i> , 2012, 12, 801-817.	28.4	851
75	Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival. <i>Cancer Research</i> , 2012, 72, 5675-5682.	0.9	109
76	Defective homologous recombination in human cancers. <i>Cancer Treatment Reviews</i> , 2012, 38, 89-100.	7.7	60
77	Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors. <i>Drug Discovery Today: Disease Models</i> , 2012, 9, e51-e58.	1.2	14
78	Targeting the S and G2 checkpoint to treat cancer. <i>Drug Discovery Today</i> , 2012, 17, 194-202.	6.4	138
79	Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012, 21, 20-26.	2.2	30
80	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 155-164.	2.3	55
81	High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1788-1788.	1.4	1
82	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. <i>Nature Medicine</i> , 2011, 17, 875-882.	30.7	238
83	Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. <i>European Journal of Cancer</i> , 2011, 47, 2052-2059.	2.8	12
84	The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 257-267.	3.2	76
85	Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of β -1-Acid Glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1847-1859.	6.4	13
86	Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e20311.	2.5	47
87	Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. <i>Biochemical Journal</i> , 2011, 436, 671-679.	3.7	56
88	PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011, 118, 429-432.	2.3	14
89	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. <i>Journal of the National Cancer Institute</i> , 2011, 103, 334-346.	6.3	235
90	The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2320-2329.	4.1	50

#	ARTICLE	IF	CITATIONS
91	The role of PARP in DNA repair and its therapeutic exploitation. British Journal of Cancer, 2011, 105, 1114-1122.	6.4	263
92	Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. British Journal of Cancer, 2011, 105, 372-381.	6.4	173
93	The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients. Methods in Molecular Biology, 2011, 780, 239-266.	0.9	5
94	Strategies Employed for the Development of PARP Inhibitors. Methods in Molecular Biology, 2011, 780, 463-489.	0.9	5
95	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry, 2010, 53, 8498-8507.	6.4	40
96	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology, 2010, 66, 807-812.	2.3	17
97	Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. British Journal of Cancer, 2010, 102, 342-350.	6.4	55
98	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer, 2010, 103, 1588-1596.	6.4	58
99	Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors. Clinical Cancer Research, 2010, 16, 2344-2351.	7.0	244
100	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research, 2010, 70, 6268-6276.	0.9	102
101	Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors. Organic and Biomolecular Chemistry, 2010, 8, 2397.	2.8	26
102	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research, 2009, 15, 1241-1249.	7.0	75
103	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics, 2009, 8, 1828-1837.	4.1	9
104	Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentialization <i>In vivo</i> ?. Clinical Cancer Research, 2009, 15, 6106-6112.	7.0	57
105	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Molecular Cancer Therapeutics, 2009, 8, 407-414.	4.1	89
106	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. British Journal of Cancer, 2009, 101, 256-262.	6.4	68
107	Poly(ADP-Ribose) Polymerase-1 and DNA-Dependent Protein Kinase Have Equivalent Roles in Double Strand Break Repair Following Ionizing Radiation. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1520-1527.	0.8	51
108	A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Research and Treatment, 2008, 111, 55-63.	2.5	19

#	ARTICLE	IF	CITATIONS
109	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4885-4890.	2.2	26
110	Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. <i>Cell Cycle</i> , 2008, 7, 3898-3907.	2.6	16
111	Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7917-7923.	7.0	361
112	Inhibition of DNA repair as a therapeutic target. , 2008, , 284-304.		0
113	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 945-956.	4.1	266
114	Structure-based design of 2-aryl amino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. <i>Organic and Biomolecular Chemistry</i> , 2007, 5, 1577.	2.8	16
115	Therapeutic potential of drugs to modulate DNA repair in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 783-799.	3.4	28
116	Pyranone, Thiopyranone, and Pyridone Inhibitors of Phosphatidylinositol 3-Kinase Related Kinases. Structure-Activity Relationships for DNA-Dependent Protein Kinase Inhibition, and Identification of the First Potent and Selective Inhibitor of the Ataxia Telangiectasia Mutated Kinase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1958-1972.	6.4	79
117	PARP Inhibitors and Cancer Therapy. , 2006, , 218-233.		5
118	Searching for Cyclin-Dependent Kinase Inhibitors Using a New Variant of the Cope Elimination. <i>Journal of the American Chemical Society</i> , 2006, 128, 6012-6013.	13.7	64
119	Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441. <i>Cancer Research</i> , 2006, 66, 5354-5362.	0.9	371
120	Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1515-1520.	2.2	89
121	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. <i>Nature</i> , 2005, 434, 913-917.	27.8	4,382
122	Potential of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1328-1337.	4.1	73
123	Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 206-213.	2.5	21
124	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1. <i>Clinical Cancer Research</i> , 2005, 11, 3402-3409.	7.0	103
125	The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks. <i>Clinical Cancer Research</i> , 2005, 11, 8449-8457.	7.0	105
126	Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7829-7846.	6.4	163

#	ARTICLE	IF	CITATIONS
127	PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine, 2005, 7, 1-20.	3.9	190
128	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells. Clinical Cancer Research, 2004, 10, 881-889.	7.0	167
129	Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361. Journal of the National Cancer Institute, 2004, 96, 56-67.	6.3	459
130	Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM. Cancer Research, 2004, 64, 9152-9159.	0.9	1,089
131	Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene, 2004, 23, 7322-7329.	5.9	98
132	N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2. Journal of Medicinal Chemistry, 2004, 47, 3710-3722.	6.4	116
133	Resistance-Modifying Agents. 11.1 Pyrimido[5,4-d]pyrimidine Modulators of Antitumor Drug Activity. Synthesis and Structure-Activity Relationships for Nucleoside Transport Inhibition and Binding to β -1-Acid Glycoprotein. Journal of Medicinal Chemistry, 2004, 47, 4905-4922.	6.4	41
134	Potential of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2433-2437.	2.2	71
135	Design, Synthesis, and Evaluation of 3,4-Dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as Inhibitors of Poly(ADP-Ribose) Polymerase. Journal of Medicinal Chemistry, 2004, 47, 5467-5481.	6.4	46
136	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 217-222.	2.2	54
137	Structure-Based design of 2-Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-Dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3079-3082.	2.2	69
138	Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 210-213.	6.4	152
139	Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotential and pharmacological studies. Clinical Cancer Research, 2003, 9, 2711-8.	7.0	59
140	Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Research, 2003, 63, 6008-15.	0.9	260
141	Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 with O6-Substituted Guanine Derivatives. Journal of Medicinal Chemistry, 2002, 45, 3381-3393.	6.4	90
142	Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotential Activity: Design, Synthesis, and X-ray Cocrystal Structure. Journal of Medicinal Chemistry, 2002, 45, 4961-4974.	6.4	130
143	Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido[5,4-d]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 108-115.	1.3	1
144	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology, 2002, 9, 745-749.	9.7	198

#	ARTICLE	IF	CITATIONS
145	Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyrindamole22Abbreviations: ENT, equilibrative nucleoside transporter; CNT, concentrative nucleoside transporter; DP, dipyrindamole; HPX, hypoxanthine; NBTI, nitrobenzylthioinosine; TdR, thymidine; Kt, kinetic constant for transport; and Tmax, maximum velocity for transport.. Biochemical Pharmacology, 2001, 61, 477-484.	4.4	9
146	Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4- d]pyrimidines that inhibit nucleoside transport in the presence of h ⁺ 1 -acid glycoprotein (AGP). Bioorganic and Medicinal Chemistry Letters, 2000, 10, 585-589.	2.2	10
147	Resistance-Modifying Agents. 9.1Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase. Journal of Medicinal Chemistry, 2000, 43, 4084-4097.	6.4	276
148	Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles. Journal of Medicinal Chemistry, 2000, 43, 2797-2804.	6.4	203
149	Resistance-Modifying Agents. 8. Inhibition of O6-Alkylguanine-DNA Alkyltransferase by O6-Alkenyl-, O6-Cycloalkenyl-, and O6-(2-Oxoalkyl)guanines and Potentiation of Temozolomide Cytotoxicity in Vitro by O6-(1-Cyclopentenylmethyl)guanine. Journal of Medicinal Chemistry, 2000, 43, 4071-4083.	6.4	49
150	Resistance-Modifying Agents. 5.1Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP). Journal of Medicinal Chemistry, 1998, 41, 5247-5256.	6.4	127
151	The quantitation by radioimmunoassay of 2â€²-deoxyuridine 5â€²-triphosphate in extracts of thymidylate synthase-inhibited cells. Analytical Biochemistry, 1989, 177, 347-352.	2.4	13
152	Modulation of dipyrindamole action by h ⁺ 1acid glycoprotein. Biochemical Pharmacology, 1989, 38, 3281-3288.	4.4	17
153	A radioimmunoassay for deoxythymidine triphosphate. Biochemical Society Transactions, 1989, 17, 1052-1052.	3.4	3
154	Potentiation of quinazoline antifolate (CB3717) toxicity by dipyrindamole in human lung carcinoma, A549, cells. Biochemical Pharmacology, 1988, 37, 2113-2120.	4.4	16
155	Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody. Journal of Hepatology, 1986, 2, 25-31.	3.7	20
156	Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo. Biochemical Society Transactions, 1980, 8, 94-94.	3.4	1
157	Implications of homologous recombination defectiveness in ovarian cancer. , 0, , 75-82.		0